BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31959052)

  • 21. Sublocalization of putative tumor suppressor gene loci on chromosome arm 14q in neuroblastoma.
    Theobald M; Christiansen H; Schmidt A; Melekian B; Wolkewitz N; Christiansen NM; Brinkschmidt C; Berthold F; Lampert F
    Genes Chromosomes Cancer; 1999 Sep; 26(1):40-6. PubMed ID: 10441004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus.
    Russell MR; Penikis A; Oldridge DA; Alvarez-Dominguez JR; McDaniel L; Diamond M; Padovan O; Raman P; Li Y; Wei JS; Zhang S; Gnanchandran J; Seeger R; Asgharzadeh S; Khan J; Diskin SJ; Maris JM; Cole KA
    Cancer Res; 2015 Aug; 75(15):3155-66. PubMed ID: 26100672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma.
    Mora J; Cheung NK; Chen L; Qin J; Gerald W
    Clin Cancer Res; 2001 May; 7(5):1358-61. PubMed ID: 11350906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of a 69-kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27.
    Qu XY; Hauptschein RS; Rzhetsky A; Scotto L; Chien MC; Ye X; Frigeri F; Rao PH; Pasqualucci L; Gamberi B; Deaven LL; Zhang P; Chaganti RS; Dalla-Favera R; Russo JJ
    DNA Seq; 1998; 9(4):189-204. PubMed ID: 10520750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes.
    Fernández-Blanco B; Berbegall AP; Martin-Vañó S; Castel V; Navarro S; Noguera R
    Neoplasia; 2021 Jan; 23(1):12-20. PubMed ID: 33190090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
    Maris JM; Guo C; Blake D; White PS; Hogarty MD; Thompson PM; Rajalingam V; Gerbing R; Stram DO; Matthay KK; Seeger RC; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):32-6. PubMed ID: 11464900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.
    Santo EE; Ebus ME; Koster J; Schulte JH; Lakeman A; van Sluis P; Vermeulen J; Gisselsson D; Øra I; Lindner S; Buckley PG; Stallings RL; Vandesompele J; Eggert A; Caron HN; Versteeg R; Molenaar JJ
    Oncogene; 2012 Mar; 31(12):1571-81. PubMed ID: 21860421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q.
    Jensen RH; Tiirikainen M; You L; Ginzinger D; He B; Uematsu K; Xu Z; Treseler P; McCormick F; Jablons DM
    Anticancer Res; 2003; 23(3B):2281-9. PubMed ID: 12894504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
    Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
    Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
    Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
    Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.
    Coco S; Defferrari R; Scaruffi P; Cavazzana A; Di Cristofano C; Longo L; Mazzocco K; Perri P; Gambini C; Moretti S; Bonassi S; Tonini GP
    J Pathol; 2005 Nov; 207(3):346-57. PubMed ID: 16178058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.
    White PS; Thompson PM; Gotoh T; Okawa ER; Igarashi J; Kok M; Winter C; Gregory SG; Hogarty MD; Maris JM; Brodeur GM
    Oncogene; 2005 Apr; 24(16):2684-94. PubMed ID: 15829979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
    Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
    Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene.
    Ejeskär K; Aburatani H; Abrahamsson J; Kogner P; Martinsson T
    Br J Cancer; 1998 Jun; 77(11):1787-91. PubMed ID: 9667647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene.
    Sinclair PB; Sorour A; Martineau M; Harrison CJ; Mitchell WA; O'Neill E; Foroni L
    Cancer Res; 2004 Jun; 64(12):4089-98. PubMed ID: 15205317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
    Maris JM; Guo C; White PS; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):24-7. PubMed ID: 11464895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.
    Pezzolo A; Rossi E; Gimelli S; Parodi F; Negri F; Conte M; Pistorio A; Sementa A; Pistoia V; Zuffardi O; Gambini C
    Neuro Oncol; 2009 Apr; 11(2):192-200. PubMed ID: 18923191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
    Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
    Yang XH; Tang F; Shin J; Cunningham JM
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors.
    Hoebeeck J; Michels E; Menten B; Van Roy N; Eggert A; Schramm A; De Preter K; Yigit N; De Smet E; De Paepe A; Laureys G; Vandesompele J; Speleman F
    Int J Cancer; 2007 Feb; 120(3):533-8. PubMed ID: 17096344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.